July 21, 2025 4:39pm

After a low heat of an advance/decline line of 17/14 and 4 flats

Earnings are a’comin: 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA)

Never above you. Never below you. Always beside you … I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Monday’s RegMed Investors’ (RMi) pre-open: volatility is still on the front burner … https://www.regmedinvestors.com/articles/14005

Friday night’s RegMed Investors (RMi) Closing Bell: Another I told you so … https://www.regmedinvestors.com/articles/14004

RegMed Investors (RMi) Research Note: Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed DOWN -19.12 points or -0.04%, the S&P closed UP +8.81 points or +0.14% while the Nasdaq closed UP +78.52 points or +0.38%

  • Theme of the session, starting the week with optimism and confidence into earnings season

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

Monday’s advance/decline line opened positive with 25 incliners, 7 decliners and 3 flats ending with a positive close of 17 incliners, 14 decliners and 4 flats  

Metrics:  Monday, the IBB was down -0.60%, the XBI was down -0.40% while the VIX was up +0.27 points or +1.65% at 16.68

 

Q3 – 7/25 – 1 market holiday, 10 positive and 4 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Monday Closing UP (10 of 17) +after Friday’s

  • Intellia Therapeutics (NTLA +$0.57 after Friday’s +$0.23),
  • Prime Medicine (PRME +$0.44 after Friday’s +$0.23),
  • Editas Medicine (EDIT +$0.39 after Friday’s +$0.03),
  • Regenxbio (RGNX +$0.33 after Friday’s -$0.53),
  • AxoGen (AXGN +$0.33 after Friday’s -$0.35),
  • Beam Therapeutics (BEAM +$0.28 after Friday’s +$0.30),
  • MiMedx (MDXG +$0.23),
  • CRISPR Therapeutics (CRSP +$0.20 after Friday’s +$10.04),
  • Vericel (VCEL +$0.12 after Friday’s -$0.92),
  • Ultragenyx (Pharmaceuticals (RARE +$0.08 after Friday’s -$1.10),

Flat (4)

  • bluebird bio (BLUE) P/E acquired
  • Blueprint Medicine (BPMC) acquired by SNY
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)

Monday’s Closing DOWN (10 of 14): 

  • Mesoblast (MESO -$0.97 after Friday’s +$3.28),
  • uniQure NV (QURE -$0.49),
  • Moderna (MRNA -$0.29 after Friday’s -$0.94)
  • Ionis Pharmaceuticals (IONS -$0.21 after Friday’s -$0.41),
  • Lenz Therapeutics (LENZ -$0.15 after Friday’s -$0.84),
  • Sage Therapeutics (SAGE -$0.14),
  • Brainstorm Cell Therapeutics (BCLI -$0.0701 after Friday’s $0.00),
  • Voyager Therapeutics (VYGR -$0.07 after Friday’s +$0.02),
  • BioLife Solutions (BLFS -$0.07 after Friday’s -$0.59),
  • Agenus (AGEN -$0.06 after Friday’s -$0.57),

 

The BOTTOM LINE:  The cell and gene therapy sector flipped share pricing burgers on high …

Some bad:

GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge, Mass workers (according to a public filing). The layoffs come months after GSK said it had planned to expand its Massachusetts presence.

Many worries:

Sarepta Therapeutics (SRPT) shares continue to slide after several IBs downgrade the stock. SRPT closed down 7%. The possibility is growing that Elevidys, its treatment for Duchenne muscular dystrophy, will be removed from the market. 2 patients have died after receiving it.

  • Also worrisome is that the company didn’t disclose the death of a third patient, who was being treated with SRP-9004, an experimental gene therapy for limb-girdle muscular dystrophy.
  • The trial is now halted…
  • The FDA has requested SRPT stop shipments of the drug, but Sarepta said it will continue to treat ambulatory patients.
  • Needham analyst Ethan Markowski said he’s “Throwing in the towel,” and Leerink analyst Joseph Schwartz said, “All Credibility Lost” as they both downgraded shares of in recent days. Mizuho also took its rating to neutral, citing “mounting concerns about Sarepta’s businesses.”

 

Earnings are a’comin: 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA)

 

Cell and gene therapy sector equities stayed Thursday within the upside suffering a few downside flips after popping on Wednesday following a dive on Tuesday post Monday’s positive sector close …

  • After popping on Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday ….
  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

As I also wrote, the “June Swoon” is well over … however, July seems to be not as bad and better than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

July evolves, understanding the “flow” …

  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

Last week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY) and Intellia Therapeutics (NTLA)
  • Friday: CRISPR Therapeutics (CRSP), Mesoblast (MESO) and Solid Biosciences (SLDB)

The worst three (3) in the session: 

  • Monday: Mesoblast (MESO), Moderna (MRNA) and uniQure NV (QURE)
  • Friday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Ultragenyx Pharmaceuticals RARE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.